Research ArticleOriginal Article
Open Access

Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia

Mohammed R. Arafah, Michael U. Youssef and Faisal M. AlSamadi
Saudi Medical Journal June 2023, 44 (6) 570-579; DOI: https://doi.org/10.15537/smj.2023.44.6.20230023

References

  1. 1.↵
    1. Kannel WB,
    2. Castelli WP,
    3. Gordon T.
    Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham study. Annals of internal Medicine 1979; 90: 85–91.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.
    1. Kannel WB,
    2. Dawber TR,
    3. Kagan A,
    4. Revotskie N,
    5. STOKES J. III.
    Factors of risk in the development of coronary heart disease—six-year follow-up experience: the Framingham Study. Ann Intern Med 1961; 55: 33–50.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.
    1. Keys A,
    2. Mienotti A,
    3. Karvonen MJ,
    4. Aravanis C,
    5. Blackburn H,
    6. Buzina R, et al.
    The diet and 15-year death rate in the seven countries study. Am J Epidemiol 1986; 124: 903–915.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.
    1. Müller C.
    Angina pectoris in hereditary xanthomatosis. Arch Intern Med 1939; 64: 675–700.
    OpenUrlCrossRefWeb of Science
  5. 5.
    1. Soppert J,
    2. Lehrke M,
    3. Marx N,
    4. Jankowski J,
    5. Noels H.
    Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev 2020; 159: 4–33.
    OpenUrl
  6. 6.↵
    1. Stamler J,
    2. Wentworth D,
    3. Neaton JD.
    Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?: findings in 356 222 primary screenees of the multiple risk factor intervention trial (mrfit). Jama 1986; 256: 2823–2828.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Afshar M,
    2. Rong J,
    3. Zhan Y,
    4. Chen HY,
    5. Engert JC,
    6. Sniderman AD, et al.
    Risks of incident cardiovascular disease associated with concomitant elevations in lipoprotein(a) and low‐density lipoprotein cholesterol—The Framingham heart study. J Am Heart Assoc 2020; 9: e014711.
    OpenUrl
  8. 8.↵
    1. Piepoli MF,
    2. Hoes AW,
    3. Agewall S,
    4. Albus C,
    5. Brotons C,
    6. Catapano AL, et al.
    Guidelines: Editor’s choice: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Mach F,
    2. Baigent C,
    3. Catapano AL,
    4. Koskinas KC,
    5. Casula M,
    6. Badimon L, et al.
    2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–188.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Visseren FLJ,
    2. Mach F,
    3. Smulders YM,
    4. Carballo D,
    5. Koskinas KC,
    6. Bäck M, et al.
    2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2021; 42: 3227–3337.
    OpenUrlCrossRefPubMed
  11. 11.
    1. Hadjiphilippou S,
    2. Ray KK.
    Cholesterol-Lowering Agents. Circ Res 2019; 124: 354–363.
    OpenUrl
  12. 12.
    1. Mach F,
    2. Baigent C,
    3. Catapano AL,
    4. Koskinas KC,
    5. Casula M,
    6. Badimon L, et al.
    2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2019; 41: 111–188.
    OpenUrlCrossRef
  13. 13.↵
    1. Reiter-Brennan C,
    2. Osei AD,
    3. Iftekhar Uddin SM,
    4. Orimoloye OA,
    5. Obisesan OH,
    6. Mirbolouk M, et al.
    ACC/AHA lipid guidelines: Personalized care to prevent cardiovascular disease. Cleve Clin J Med 2020; 87: 231–239.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Sheridan A,
    2. Wheeler-Jones CPD,
    3. Gage MC.
    The Immunomodulatory Effects of Statins on Macrophages. Immuno 2022; 2: 317–343.
  15. 15.
    1. De Backer G,
    2. Jankowski P,
    3. Kotseva K,
    4. Mirrakhimov E,
    5. Reiner Ž,
    6. Rydén L, et al.
    Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019; 285: 135–146.
    OpenUrlPubMed
  16. 16.↵
    1. Zafeiropoulos S,
    2. Farmakis I,
    3. Kartas A,
    4. Arvanitaki A,
    5. Pagiantza A,
    6. Boulmpou A, et al.
    Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial. Atherosclerosis 2021; 323: 37–43.
    OpenUrlPubMed
  17. 17.↵
    1. Sud M,
    2. Han L,
    3. Koh M,
    4. Abdel-Qadir H,
    5. Austin PC,
    6. Farkouh ME, et al.
    Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention. J Am Coll Cardiol 2020; 76: 1440–1450.
    OpenUrlFREE Full Text
  18. 18.↵
    1. Al Sifri SN,
    2. Almahmeed W,
    3. Azar S,
    4. Okkeh O,
    5. Bramlage P,
    6. Jünger C, et al.
    Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One 2014; 9: e84350.
    OpenUrl
  19. 19.↵
    1. Al Sifri S,
    2. Al Shammeri O,
    3. Al Jaser S,
    4. Alkhenizan A,
    5. Bin Shafi Shafiurrehman A,
    6. Morcos B, et al.
    Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia. Saudi Med J 2018; 39: 697–704.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Alhabib KF,
    2. Kinsara AJ,
    3. Alghamdi S,
    4. Al-Murayeh M,
    5. Hussein GA,
    6. AlSaif S, et al.
    The first survey of the Saudi Acute Myocardial Infarction Registry Program: Main results and long-term outcomes (STARS-1 Program). PLoS One 2019; 14: e0216551.
    OpenUrl
  21. 21.↵
    1. Navar AM,
    2. Matskeplishvili ST,
    3. Urina-Triana M,
    4. Arafah M,
    5. Chen J-W,
    6. Sukonthasarn A, et al.
    Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries. Clinical Cardiology 2021; 44: 955–962.
    OpenUrl
  22. 22.
    1. Lala V,
    2. Zubair M,
    3. Minter DA.
    Liver function tests. Treasure Island (FL): StatPearls Publishing; 2022.
  23. 23.
    1. Sundjaja JH,
    2. Pandey S.
    Cholesterol Screening. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
  24. 24.
    Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes Care 2021; 44: S15–S33.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. AlHabib KF,
    2. Hersi A,
    3. AlFaleh H,
    4. Kurdi M,
    5. Arafah M,
    6. Youssef M, et al.
    The Saudi Project for Assessment of Coronary Events (SPACE) registry: design and results of a phase I pilot study. Can J Cardiol 2009;25: e255–e258.
    OpenUrlPubMed
  26. 26.↵
    1. El‐Menyar A,
    2. Zubaid M,
    3. Shehab A,
    4. Bulbanat B,
    5. AlBustani N,
    6. Alenezi F, et al.
    Prevalence and impact of cardiovascular risk factors among patients presenting with acute coronary syndrome in the middle East. Clinical cardiology. 2011; 34: 51–58.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Hagström E,
    2. Steg PG,
    3. Szarek M,
    4. Bhatt DL,
    5. Bittner VA,
    6. Danchin N, et al.
    Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation 2022; 146: 657–672.
    OpenUrl
  28. 28.
    1. Ostadal P,
    2. Steg PG,
    3. Poulouin Y,
    4. Bhatt DL,
    5. Bittner VA,
    6. Chua T, et al.
    Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2022; 10: 330–340.
    OpenUrl
  29. 29.↵
    1. Walli-Attaei M,
    2. Rosengren A,
    3. Rangarajan S,
    4. Breet Y,
    5. Abdul-Razak S,
    6. Sharief WA, et al.
    Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. Lancet (London, England). 2022; 400: 811–821.
    OpenUrl
  30. 30.↵
    1. Holthuis EI,
    2. Visseren FLJ,
    3. Bots ML,
    4. Peters SAE.
    Risk Factor clusters and cardiovascular disease in high-risk patients: The UCC-SMART Study. Glob Heart 2021; 16: 85.
    OpenUrl
  31. 31.↵
    1. Roe MT,
    2. Li QH,
    3. Bhatt DL,
    4. Bittner VA,
    5. Diaz R,
    6. Goodman SG, et al.
    Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation 2019; 140: 1578–1589.
    OpenUrl
  32. 32.↵
    1. Landmesser U,
    2. Pirillo A,
    3. Farnier M,
    4. Jukema JW,
    5. Laufs U,
    6. Mach F, et al.
    Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. Atheroscler Suppl 2020; 42: e49–e58.
    OpenUrl
  33. 33.↵
    1. Banach M,
    2. Penson PE,
    3. Vrablik M,
    4. Bunc M,
    5. Dyrbus K,
    6. Fedacko J, et al.
    Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res 2021; 166: 105499.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Claessen BE,
    2. Guedeney P,
    3. Gibson CM,
    4. Angiolillo DJ,
    5. Cao D,
    6. Lepor N, et al.
    Lipid management in patients presenting with acute coronary syndromes: A review. J Am Heart Assoc 2020; 9: e018897.
    OpenUrl
  35. 35.
    1. Rea F,
    2. Corrao G,
    3. Merlino L,
    4. Mancia G.
    Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J 2018; 39: 3654–3661.
    OpenUrl
  36. 36.
    1. Banach M,
    2. Penson PE.
    Drucebo effect–the challenge we should all definitely face! Archives of Medical Science: AMS 2021; 17: 542.
    OpenUrl
  37. 37.↵
    1. Penson PE,
    2. Mancini GJ,
    3. Toth PP,
    4. Martin SS,
    5. Watts GF,
    6. Sahebkar A, et al.
    Introducing the ‘Drucebo’effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions. J Cachexia Sarcopenia Muscle 2018; 9: 1023–1033.
    OpenUrl
  38. 38.↵
    1. Alasnag M,
    2. Awan Z,
    3. Al Ghamdi A,
    4. Al Modaimeigh H,
    5. Al Shemiri M.
    Improvement initiative in LDL-C management in Saudi Arabia: A call to action. IJC Heart Vasc 2020; 31: 100667.
    OpenUrl
  39. 39.↵
    1. Al-Shehri AM.
    Prevalence and pattern of lipid disorders in Saudi patients with angiographically documented coronary artery disease. J Fam Community Med 2014; 21: 166–169.
    OpenUrl
  40. 40.↵
    1. Athyros VG,
    2. Stavropoulos K,
    3. Imprialos KP,
    4. Doumas M.
    Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data. Int J Cardiol 2020; 316: 240–241.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords